Molecular mechanisms of resistance of leukemia to imatinib mesylate

Leukemia Research

Volumn 28, Issue SUPPL. 1, 2004, Pages 39-45

  Tauchi, Tetsuzo ^a   Ohyashiki, Kazuma ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

BCR ABL; CML; Imatinib; Tyrosine kinase

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 5 AZA 2' DEOXYCYTIDINE; ADAPHOSTIN; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BAG 1 PROTEIN; BCR ABL PROTEIN; BORTEZOMIB; FR 901228; GRN 163; HISTONE DEACETYLASE INHIBITOR; HOMOHARRINGTONINE; IMATINIB; LONAFARNIB; OBLIMERSEN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PROTEASOME INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN SYNTHESIS INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; TELOMERASE INHIBITOR; TELOMESTATIN; UNCLASSIFIED DRUG;

CELL HETEROGENEITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DOSE CALCULATION; DRUG DOSE REGIMEN; DRUG MECHANISM; GENE AMPLIFICATION; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHATIC LEUKEMIA; MELANOMA; MOLECULAR MECHANICS; MULTIPLE MYELOMA; MUTATION; PRIORITY JOURNAL; REVIEW;

EID: 1342343033     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.10.007     Document Type: Article

References (82)

1. Tauchi T., Broxmeyer H.E. BCR/ABL signal transduction. Int. J. Hematol. 61:1995;105-112.
2. Konopka J.B., Watanabe S.M., Witte O.N. An alternation of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell. 37:1984;1035-1042.
3. Lugo T.G., Pendergast A.M., Muller A.J., Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 247:1990;1079-1082.
4. Sawyers C.L. Chronic myeloid leukemia. N. Engl. J. Med. 340:1999;1330-1340.
5. Faderl S., Talpaz M., Estrov Z., Kantarjian H.M. Chronic myelogenous leukemia: biology and therapy. Ann. Intern. Med. 131:1999;207-219.
6. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by P210bcr/abl gene of the Philadelphia chromosome. Science. 247:1990;824-830.
7. Heisterkamp N., Jenster G., ten Hoeve J., Zovich D., Pattengale P.K., Groffen J. Acute leukemia in bcr/abl transgenic mice. Nature. 344:1990;251-253.
8. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S.et al. Efficacy of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL-positive cells. Nat. Med. 2:1996;561-566.
9. Buchdunger E., Zimmermann J., Mett H., Meyer T., Muller M., Druker B.J. et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56:1996;100-104.
10. Heinrich M.C., Griffith D.J., Druker B.J., Wait C.L., Ott K.A., Zigler A.J. Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood. 96:2000;925-932.
11. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Structural mechanism for STI571 inhibition of abelson tyrosine kinase. Science. 289:2000;1938-1942.
12. Azam M., Latek R.R., Daley G.Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 112:2003;831-843.
13. Gambacorti-Passerini C.B., Gunby R.H., Piazza R., Galietta A., Rostagno R., Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukemias. Lancet Oncol. 4:2003;75-85.
14. Gambacorti-Passerini C., Barni R., le Coutre P., Zucchetti M., Cabrita G., Cleris L.et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL (+) leukemic cells to the abl inhibitor STI571. J. Natl. Cancer Inst. 92:2000;1641-1650.
15. Gambacorti-Passerini C., le Coutre P., Zucchetti M., D'Incalci M. Binding of imatinib by α1-acid glycoprotein. Blood. 100:2002;367-368.
16. Marbach P., Lemaire M., Hayes M., Elmquist W.F. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J. Pharmacol. Exp. Ther. 304:2003;1085-1092.
17. Hegedus T., Orifi L., Seprodi A., Varadi A., Sarkadi B., Keri G. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochem. Biophys. Acta. 1587:2002;318-325.
18. Mahon F.X., Belloc F., Lagarde V., Chollet C., Moreau-Gaudry F., Reiffers J.et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood. 101:2003;2368-2373.
19. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N.et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 293:2001;876-880.
20. Gambacorti-Passerini C., Rossi F., Verga M., Ruchatz H., Gunby R., Frapolli R.et al. Differences between in vivo and in vitro sensitivity to imatinib of BCR-ABL positive cells obtained from leukemia patients. Blood Cells Mol. Dis. 28:2002;361-372.
21. Hochhaus A., Kreil S., Corbin A.S., La Rosee P., Muller M.C., Lahaye T. et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 16:2003;2190-2196.
22. Weisberg E., Griffin J.D. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood. 95:2000;3498-3505.
23. Mahon F.X., Deininger M.W., Schultheis B., Chabrol J., Reiffers J., Goldman J.M.et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 96:2000;1070-1079.
24. Sirulink A., Silver R.T., Najfeld V. Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI571. Leukemia. 15:2001;1795-1797.
25. Campbell L.J., Patsouris C., Rayeroux K.C., Somana K., Januszewics E.H., Szer J. BCR-ABL amplification in chronic myelocytic leukemia blastic crisis following imatinib mesylate administration. Cancer Genet. Cytogenet. 139:2002;30-33.
26. Morel F., Le Bris M.J., Herry A., La Calvez G., Marion V., Abgrall J.F. et al. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. Eur. J. Hematol. 70:2003;235-239.
27. Tipping A.J., Mahon F.X., Lagarde V., Goldman J.M., Melo J.V. Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells. Blood. 98:2001;3864-3867.
28. Von Bubnoff N., Schneller F., Peschel C., Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome- positive leukaemia to STI571: a prospective study. Lancet. 359:2002;487-491.
29. Hofmann W.K., Jones L.C., Lemp N.A., de Vos S., Gschaidmeier H., Hoelzer D.et al. Ph acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood. 99:2002;1860-1862.
30. Branford S., Rudzki Z., Walsh S., Grigg A., Arthur C., Taylor K.et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR-ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemias who develop imatinib (STI571) resistance. Blood. 99:2002;3472-3475.
31. Roche-Lestienne C., Soenen-Cornu V., Gradel-Duflos N., Lai J.L., Philippe N., Facon T.et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood. 100:2002;1014-1018.
32. Roumiantsev S., Shah N.P., Gorre M.E., Nicoll J., Brasher B.B., Sawyers C.L.et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain p-loop. Proc. Natl. Acad. Sci. U.S.A. 99:2002;10700-10705.
33. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor (STI571) in chronic phase and blastic crisis chronic myeloid leukemia. Cancer Cell. 2:2002;117-125.
34. Ricci C., Scappini B., Divoky V., Gatto S., Onida F., Verstovsek S.et al. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. Cancer Res. 62:2002;5995-5998.
35. Corbin A.S., La Rosee P., Stoffregen E.P., Druker B.J., Deininger M.W. Several BCR-ABL kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood. 101:2003;4611-4614.
36. Branford S., Rudzki Z., Walsh S., Parkinson I., Grigg A., Szer J.et al. The detection of BCR-ABL mutations in imatinib-treated CML patients is virtually always accompanied by clinical resistance and mutations in the ATP phosphate-binding loop (P-loop) are associated with poor prognosis. Blood. 102:2003;276-283.
37. Nagar B., Bornmann W.G., Pellicena P., Schnidler T., Veach D.R., Miller W.T.et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecular inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62:2002;4236-4243.
38. La Rosee P., Corbin A.S., Stoffregen E.P., Deininger M.W., Druker B.J. Activity of the BCR-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res. 62:2002;7149-7153.
39. Huron D.R., Gorre M.E., Kraker A.J., Sawyers C.L., Rosen N., Moasser M.M. A novel pyridopyrimidine inhibitor of Abl kinase is a picomolar inhibitor of BCR-ABL-driven K562 cells and is effective against STI571-resistant BCR-ABL mutants. Clin. Cancer Res. 9:2003;1267-1273.
40. Reichert A., Heisterkamp N., Daley G.Q., Groffen J. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in p190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood. 97:2001;1399-1403.
41. Peters D.G., Hoover R.R., Gerlach M.J., Koh E.Y., Zhang H., Choe K.et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR-ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 97:2001;1404-1412.
42. Hoover R.R., Mahon F.X., Melo J.V., Daley G.Q. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood. 100:2002;1068-1071.
43. Brodsky A.L. Apoptotic synergism between STI571 and the farnesyl transferase inhibitor SCH66336 on an imatinib-sensitive cell line. Blood. 101:2003;2070.
44. Nakajima A., Tauchi T., Sumi M., Bishop W.R., Ohyashiki K. Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells. Mol. Cancer Ther. 2:2003;219-224.
45. Reuter C.W.M., Morgan M.A., Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood. 96:2000;1655-1669.
46. Sebti S.M., Hamilton A.D. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene. 19:2000;6584-6593.
47. Liu M., Bryant M.S., Chen J., Lee S., Yaremko B., Lipari P.et al. Antitumor activity of SCH66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res. 58:1998;4947-4956.
48. Ashar H.R., James L., Gray K., Carr D., Black S., Armstrong L.et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J. Biol. Chem. 275:2000;30451-30457.
49. Wang E., Casciano C.N., Clement P.R., Johnson W.W. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein. Cancer Res. 61:2001;7525-7529.
50. Cortes J., Giles F., O'Brien S., Thomas D., Garcia-Manero G., Riso M.B. et al. Results of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood. 102:2003;82-86.
51. Raynaud F.I., Orr R.M., Goddard P.M., Lacey H.A., Lancashire H., Judson I.R.et al. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense of bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J. Pharmacol. Exp. Ther. 281:1997;420-427.
52. Webb A., Cunningham D., Cotter F., Clarke P.A., di Stefano F., Ross P.et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet. 349:1997;1137-1141.
53. Jansen B., Schlagbauer-Wadl H., Brown B.D., Bryan R.N., van Elsas A., Muller M.et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med. 4:1998;232-234.
54. Jansen B., Wacheck V., Heere-Ress E., Schlagbauer-Wadl H., Hoeller C., Lucas T.et al. Chemosensitisation of malignant melanoma by BCL-2 antisense therapy. Lancet. 356:2000;1728-1733.
55. Lopes de Menezes D.E., Hudon N., Mclntosh N., Mayer L.D. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin. Cancer Res. 6:2000;2891-2902.
56. Miyake H., Tolcher A., Gleave M.E. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J. Natl. Cancer Inst. 92:2000;34-41.
57. Wacheck V., Heere-Ress E., Halaschek-Wiener J., Lucas T., Meyer H., Eichler H.G.et al. Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model. J. Mol. Med. 79:2001;587-593.
58. Chi K.N., Gleave M.E., Klasa R., Murray N., Bryce C., Lopes de Menezes D.E.et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense™) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin. Cancer Res. 7:2001;3920-3927.
59. Lopes de Menezes D.E., Mayer L.D. Phamacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. Cancer Chemother. Pharmacol. 49:2002;57-68.
60. Rudin C.M., Otterson G.A., Mauer A.M., Villalona-Calero M.A., Tomek R., Prange B.et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann. Oncol. 13:2002;539-545.
61. Marcucci G., Byrd J.C., Dai G., Klisovic M.I., Youg D.C., Cataland S.R. et al. Phase I and pharmacodynamic studies of G3139, a bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood. 102:2003;425-432.
62. Tauchi T., Sumi M., Nakajima A., Sashida G., Shimamoto T., Ohyashiki K. Bcl-2 antisense oligonucleotide, Genasense™, is active against imatinib-resistant BCR-ABL-positive cells. Clin. Cancer Res. 9:2003;4267-4273.
63. Iwama H., Ohyashiki K., Ohyashiki J.H., Hayashi S., Kawakubo K., Shay J.W.et al. The relationship between telomere length and therapy-associated cytogenetic responses in patients with chronic myelogenous leukemia. Cancer. 79:1997;1552-1560.
64. Ohyashiki K., Ohyashiki J.H., Iwama H., Hayashi S., Shay J.W., Toyama K. Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression. Leukemia. 11:1997;190-194.
65. Ohyashiki J.H., Sashida G., Tauchi T., Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. Oncogene. 21:2002;680-687.
66. Tauchi T., Nakajima A., Sashida G., Shimamoto T., Ohyashiki J.H., Abe K.et al. Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib. Clin. Cancer Res. 8:2002;3341-3347.
67. Vigneri P., Wang J.Y.J. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat. Med. 7:2001;228-234.
68. Perkins C., Kim C.N., Fang G., Bhalla K.N. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express BCR-ABL or overexpressed MDR, MRP, Bcl-2, or Bcl-XL. Blood. 95:2000;1014-1022.
69. Puccetti E., Guller S., Orleth A., Bruggenolte N., Hoelzer D., Ottmann O.G.et al. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Cancer Res. 60:2000;3409-3413.
70. Porosnicu M., Nimmanapalli R., Nguyen D., Worthington E., Perkin C., Bhalla K.N. Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against BCR-ABL-positive acute leukemia cells. Leukemia. 15:2001;772-778.
71. Adams J., Palombella V.J., Sausville E.A., Johnson J., Destree A., Lazarus D.D.et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59:1999;2615-2622.
72. Hamdane M., David-Cordonnier M.H., D'Halluin J.C. Activation of p65 NF-kappaB protein by p210 BCR-ABL in a myeloid cell line (p210 BCR-ABL activates p65 NF-kappaB). Oncogene. 15:1997;2267-2275.
73. Reuther J.Y., Reuther G.W., Cortez D., Pendergast A.M., Baldwin A.S. Jr. A requirement of NF-kappaB activation in BCR-ABL-mediated transformation. Genes Dev. 12:1998;968-981.
74. Gatto S.R., Scappini B., Verstovsek S., Milella M., Onida F., Ball G.et al. In vitro effects of PS-341 alone and in combination with STI571 in BCR-ABL positive cell lines both sensitive and resistant to STI571. Blood. 98:2001;101a.
75. Zion M., Ben-Yehuda D., Avraham A., Cohen O., Wetzler M., Melloul D.et al. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc. Natl. Acad. Sci. U.S.A. 91:1994;10722-10726.
76. Ben-Yehuda D., Krichevsky S., Rachmilewitz E.A., Avraham A., Palumbo G.A., Frassoni F.et al. Molecular follow-up of disease progression and interferon therapy in chronic myelocytic leukemia. Blood. 90:1997;4918-4923.
77. Issa J.P., Garcia-Manero G., Mnnari R., Thomas D., Giles F., Cortes J.et al. Minimal effective dose of hypomethylating agent decitabine in hematopoietic malignancies. Blood. 98:2001;594a.
78. Kantarjian H.M., Talpaz M., Smith T.L., Cortes J., Giles F.J., Rios M.B.et al. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J. Clin. Oncol. 18:2000;3512-3513.
79. Gorre M.E., Ellwood-Yen K., Chiosis G., Rosen N., Sawyers C.L. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood. 100:2002;3041-3044.
80. Klejman A., Rushen L., Morrione A., Slupianek A., Skorski T. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene. 21:2002;5868-5876.
81. Hilger R.A., Kredke S., Hedley D., Moeller J.G., Bauer R.J., Stellberg W.et al. Erk1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006. Int. J. Clin. Pharmacol. Ther. 40:2002;567-568.
82. Druker B.J. Sem. Hematol. 40:2003;50-58.